Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.

NCT07117474 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Subjects With Mild Hypertension

Interventions

DRUG: HRS-9563, placebo

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.